What lowers your risk
- Don't smoke, and get help quitting if you do — smoking roughly doubles pancreatic cancer risk, and about 25% of cases are linked to it
- Work toward a healthy body weight — obesity raises risk by about 20%
- Limit heavy alcohol use, which drives the chronic pancreatitis that raises risk
- Ask about diabetes screening and control, especially new type 2 diabetes after 50
- If pancreatic cancer runs in your family, ask for genetic counseling — inherited gene changes cause up to 10% of cases
- Build your plate around vegetables, fruit and whole grains; limit processed and red meat
Who is at higher risk
- People who smoke, carry excess weight, or have long-standing or new-onset type 2 diabetes
- People with chronic pancreatitis, especially from heavy alcohol use or an inherited PRSS1 mutation
- People with BRCA1 or BRCA2, Lynch syndrome, CDKN2A/p16, or Peutz–Jeghers syndrome
- People with two or more first-degree relatives with pancreatic cancer, even without a known mutation
- African Americans, reflecting higher population rates of diabetes, smoking and excess weight
Screening: who it is for, and who it is not
There is no recommended screening test for pancreatic cancer in average-risk adults. In 2019 the US Preventive Services Task Force gave general-population screening a Grade D — it recommends against it — because the disease is uncommon, no test is accurate enough, and false positives lead to real harm.
That does not apply if you are high risk. The International Cancer of the Pancreas Screening (CAPS) Consortium recommends structured surveillance for people with a qualifying family history or a germline mutation, carried out at centers with genuine expertise. It uses endoscopic ultrasound alternating with MRI/MRCP, generally starting no earlier than age 50 — or 10 years before the age your youngest affected relative was diagnosed — repeated yearly if nothing concerning turns up (PMID 31672839).
CAPS is honest that whether surveillance saves lives is still being evaluated. We will not tell you it is proven when it is not.
Signs worth reporting promptly
- Yellowing of the skin or eyes, often with dark urine and pale stools
- Pain in the upper belly or back that does not go away
- Unexplained weight loss and loss of appetite
- New diabetes — or a sudden worsening of existing diabetes — after 50
- Nausea, feeling full quickly, or new digestive trouble
- Fatigue that rest does not fix
What treatment involves
When the cancer is caught before it spreads, surgery to remove it — often a Whipple procedure — offers the best chance at long-term control, usually paired with chemotherapy before and/or after.
Many pancreatic cancers are found borderline resectable, touching major blood vessels. Chemotherapy such as FOLFIRINOX is used first. The role of radiation here is genuinely evolving, and we will be straight with you about it: the one randomized trial built to test it, A021501, found that adding hypofractionated radiation to chemotherapy did not improve outcomes for borderline resectable disease. The radiation arm closed early after showing fewer clean surgical margins and shorter median survival (17.1 vs 29.8 months) than chemotherapy alone (PMID 35834226). Chemotherapy alone is now the reference approach, and radiation is used more selectively — often to control a tumor locally when surgery is not possible.
For cancer that has spread, treatment focuses on chemotherapy to control disease and ease symptoms, with radiation used to relieve pain or a blockage rather than to cure.
Honest framing: five-year relative survival is 44% when caught localized, 17% once it reaches nearby nodes, and 3% once it reaches distant organs — about 13% across all stages, because most cases are found after spread. Supportive care for pain, nutrition and emotional strain from day one is not giving up. It improves how you live at every stage.
Questions to ask your care team
- Is my tumor resectable, borderline resectable, or advanced — and what does that change?
- Would chemotherapy before surgery help me, and does radiation have a role in my case?
- Am I a candidate for a clinical trial?
- Given my family history, should I or my relatives see a genetic counselor?
- What symptom and nutrition support can I start now, not later?
- What does the surgery involve, and what is recovery actually like?
Where these numbers come from
Survival figures: American Cancer Society SEER-based statistics. Surveillance guidance: CAPS Consortium, Gut 2020 (PMID 31672839). Screening recommendation: USPSTF 2019, Grade D. Radiation evidence: A021501, JAMA Oncology 2022 (PMID 35834226). Where we could not verify a figure, we left it out.
Talk with our team
Every case is different. If you or a family member is facing this, we will help you understand your options.